Clinical Trials Logo

Flushing clinical trials

View clinical trials related to Flushing.

Filter by:

NCT ID: NCT03881644 Completed - Clinical trials for Migraine Without Aura

PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Start date: July 17, 2018
Phase: N/A
Study type: Interventional

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

NCT ID: NCT03831542 Completed - Clinical trials for Diminished Ovarian Reserve

Effect of Follicular Flushing in Patients With Mono-follicular Growth Undergoing In Vitro Fertilization

Start date: February 19, 2019
Phase:
Study type: Observational

Retrieval of an oocyte from a follicle relies on the release of the cumulus-oocyte-complex (COC) from the follicular wall into the lumen, thereby allowing aspiration by a needle. Flushing the follicle with multiple aspirations from the same follicle is used as a means to increase the ratio of COC per aspirated follicle. Data showed that follicular flushing is not superior to direct aspiration either in normally responding patients or in poor responders undergoing in vitro fertilization (IVF). There is no data in the literature regarding the issue in patients with mono-follicular growth. Direct aspiration or repeatedly flushing the follicle for those with a single follicle will be investigated.

NCT ID: NCT03530488 Not yet recruiting - Clinical trials for Pain During Hystroscopy

The Value of Endocervical and Endometrial Lidocaine Flushing Before Office Hystroscopy

Start date: May 2018
Phase: Phase 4
Study type: Interventional

women candidate for office hystroscopy were randomized to either flushing of the endocervix and endometrium with 4 ml lidocaine 2% diluted in 15 ml normal saline or 19 ml normal saline before office hystroscopy

NCT ID: NCT03508869 Terminated - Clinical trials for Erythema and Flushing Associated With Rosacea

Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea

Start date: September 27, 2016
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of Mirvaso® Gel and Dysport® for erythema and flushing of Rosacea.

NCT ID: NCT03497442 Completed - Clinical trials for Alcohol-Related Disorders

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Start date: July 12, 2018
Phase: Early Phase 1
Study type: Interventional

Asian Flushing Syndrome (AFS) is a genetic disease affecting approximately 70% of patients of East Asian descent characterized by severe flushing with minimal ethanol consumption. This reaction is cosmetically unattractive and socially limiting. Many Asian patients avoid drinking alcohol on dates, at weddings, and during business events because of this reaction and the perception of being drunk or alcoholic. Ethanol is normally metabolized to acetic acid by two enzymes. The first enzyme, alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde. The second enzyme, aldehyde dehydrogenase 2 (ALDH2) converts the toxic acetaldehyde to harmless acetic acid. When ADH function is increased or ALDH2 function is decreased, the toxic intermediate acetaldehyde accumulates resulting in cutaneous flushing. Over 70% of East Asians have genetic polymorphisms in either ADH or ALDH2 leading to intense flushing with ethanol consumption. There are no effective topical treatments for the Asian Flushing Syndrome. Oral antihistamines have been used with some success in treating symptoms of Asian Flushing Syndrome; however these can have sedating effects and may be dangerous in combination with alcohol. Brimonidine is a selective α2-adrenoceptor agonist that acts through vasoconstriction and is commercially available in a topical gel. This topical treatment is FDA approved for the indication of facial flushing and has a long history of safety in human subjects.

NCT ID: NCT03461601 Completed - Clinical trials for Unexplained Infertility

Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility

Start date: June 1, 2014
Phase: N/A
Study type: Interventional

A prospective randomized study included 210 women with Unexplained infertility subjected to combined ovarian stimulation and Intrauterine insemination (IUI). Two equal groups. Study group, subjected to uterine flushing with Human chorionic gonadotropin (HCG) one day before IUI and control group subjected to IUI alone.

NCT ID: NCT03370848 Completed - Dyslipidemias Clinical Trials

Effects of Psyllium on Niacin Tolerability

Start date: March 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether psyllium is effective in reducing flushing due to niacin and also to measure the effect of niacin on cholesterol levels.

NCT ID: NCT03354858 Completed - Infertility Clinical Trials

Follicular Flushing Versus Direct Aspiration

Start date: December 1, 2017
Phase:
Study type: Observational

The purpose of this study is to investigate the impact of follicular flushing on the oocyte recovery rate, oocyte maturity, fertilization rate, and embryo development and utilization as compared to direct aspiration (no flushing) in women undergoing IVF treatment

NCT ID: NCT03353285 Recruiting - Infertility Clinical Trials

Effect of Follicle Flushing on Oocyte Fertilization Rate

Start date: November 27, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the impact of follicular flushing on fertilization rate in women undergoing IVF treatment

NCT ID: NCT03149419 Completed - Clinical trials for Endothelial Dysfunction

Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments

Start date: March 1, 2016
Phase: Phase 4
Study type: Interventional

Hot flashes, vasomotor symptoms that affect many postmenopausal women, are associated with cardiovascular disease and endothelial dysfunction. Estrogen therapy, associated or not with progestogens, is the standard treatment for vasomotor symptoms and improves the endothelial function of postmenopausal women with hot flushes, even those with cardiovascular risk factors, such as hypertension. It is not known whether hot flushes are a cause for the development of endothelial dysfunction or are markers of this dysfunction, evidenced by estrogen deficiency, thus representing primitive target organ (vessel) lesion. Paroxetine was approved by the FDA as a non hormonal treatment for menopausal hot flashes. In this double-blind randomized clinical trial, the vascular effects of paroxetine at a dose of 7.5 mg / day, compared to placebo, during 12 weeks are evaluated.